“…We considered such variants to be of unproven pathogenicity in a Mendelian disease setting in accordance with current standards. The genes F5, 31,32 ExAC and therefore it cannot underlie a high-penetrance autosomal dominant disorder. Indeed, the authors 41 reporting this mutation observed it in a single pedigree in which 2 cases and no unaffected relatives were screened, and decided that its absence in a mere 45 control samples was sufficient to infer causality for the child's Alport syndrome and the mother's hearing loss.…”
Key Points
Developed a targeted sequencing platform covering 63 genes linked to heritable bleeding, thrombotic, and platelet disorders. The ThromboGenomics platform provides a sensitive genetic test to obtain molecular diagnoses in patients with a suspected etiology.
“…We considered such variants to be of unproven pathogenicity in a Mendelian disease setting in accordance with current standards. The genes F5, 31,32 ExAC and therefore it cannot underlie a high-penetrance autosomal dominant disorder. Indeed, the authors 41 reporting this mutation observed it in a single pedigree in which 2 cases and no unaffected relatives were screened, and decided that its absence in a mere 45 control samples was sufficient to infer causality for the child's Alport syndrome and the mother's hearing loss.…”
Key Points
Developed a targeted sequencing platform covering 63 genes linked to heritable bleeding, thrombotic, and platelet disorders. The ThromboGenomics platform provides a sensitive genetic test to obtain molecular diagnoses in patients with a suspected etiology.
“…Despite this important observation, platelet FV is not routinely evaluated in FV-deficient patients and only 3 other studies report platelet FV levels in patients with severe FV deficiency. [32][33][34] No platelet FV antigen or activity could be demonstrated in 2 patients with undetectable plasma FV. 32,33 In another FV-deficient patient, platelet FV could be visualized by Western blotting, but its activity was not determined.…”
Coagulation factor V (FV), present in plasma and platelets, is indispensable to thrombin formation, yet patients with undetectable plasma FV seldom experience major bleeding. We used thrombin generation assays to explore the role of platelet
“…[8][9][10][11][12][13] A possible explanation for the recurrence of the Arg2074Cys mutation is the involvement of a CpG mutation hot spot. On the other hand, the presence of a different mutation not involving a CpG dinucleotide at the same residue in FV (Arg2074His), as well as of several hemophilia A-causing mutations in the corresponding residue of FVIII, points to the important role of this amino acid for FV synthesis and secretion.…”
Section: Discussionmentioning
confidence: 99%
“…5 The genetic basis of severe or moderately severe type I FV deficiency is still poorly explored (up to now, a total of 12 mutations scattered through F5 have been identified). [8][9][10][11][12][13] Most mutations are nonsense, frameshift, or splicing mutations, giving rise to null alleles, whereas only 3 missense mutations have been identified. An additional 8 mutations causing FV deficiency have been reported in the heterozygous state, 5 of which were found in patients who carried the FV Leiden mutation on the second allele, leading to the "pseudohomozygous APC-resistance" condition.…”
Factor V (FV) deficiency is a rare bleeding disorder whose genetic basis has been described in a relatively small number of cases. Among a total of 12 genetic defects reported in severely or moderately severe deficient patients, 3 were missense mutations and in no case was the mechanism underlying the deficiency explored at the molecular level. In this study, a homozygous missense mutation at cDNA
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.